Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$104.04 +0.0%	$101.41	$76.53 ▼ $131.49	$24.99B	1.07	995,458 shs	890,817 shs
TAK Takeda Pharmaceutical	$15.29 +0.8%	$14.75	$12.57 ▼ $15.37	$48.64B	0.39	1.95 million shs	769,022 shs
TEVA Teva Pharmaceutical Industries	$15.65 +4.2%	$15.19	$12.47 ▼ $22.80	$17.75B	0.72	12.29 million shs	10.59 million shs
VTRS Viatris	$8.40 +1.8%	$8.80	$6.85 ▼ $13.55	$10.03B	0.91	9.93 million shs	8.66 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.94%	+2.15%	+9.53%	-16.33%	+19.25%
TAK Takeda Pharmaceutical	+0.93%	+1.54%	+0.76%	+13.34%	+16.42%
TEVA Teva Pharmaceutical Industries	+1.01%	+13.01%	-0.17%	-30.30%	+8.83%
VTRS Viatris	+1.48%	+8.98%	-4.95%	-26.34%	-28.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.3924 of 5 stars	4.4	2.0	0.0	2.2	0.8	0.0
TAK Takeda Pharmaceutical	2.5896 of 5 stars	0.0	4.0	1.7	2.7	0.0	2.5
TEVA Teva Pharmaceutical Industries	3.1153 of 5 stars	3.4	5.0	0.8	2.9	0.8	0.6
VTRS Viatris	2.505 of 5 stars	2.9	3.0	2.5	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.89	Moderate Buy	$143.44	37.87% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	49.68% Upside
VTRS Viatris	1.75	Reduce	$10.50	25.07% Upside

Current Analyst Ratings Breakdown

Latest VTRS, TAK, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
3/7/2025	VTRS Viatris	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $13.00
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
3/5/2025	VTRS Viatris	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$14.00 ➝ $10.00
2/28/2025	VTRS Viatris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$12.00 ➝ $9.00
2/28/2025	VTRS Viatris	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$11.00 ➝ $10.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	9.08	$4.47 per share	23.25	$92.17 per share	1.13
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.58 per share	4.27	$15.39 per share	0.99
TEVA Teva Pharmaceutical Industries	$16.54B	1.07	$3.10 per share	5.05	$4.75 per share	3.30
VTRS Viatris	$14.74B	0.68	$3.98 per share	2.11	$17.06 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	38.21	9.26	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.95	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)
VTRS Viatris	$54.70M	-$0.53	N/A	3.27	N/A	-5.87%	16.46%	7.09%	5/8/2025 (Estimated)

Latest VTRS, TAK, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	VTRS Viatris	$0.52	N/A	N/A	N/A	$3.30 billion	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
5/5/2025	Q1 2025	BNTX BioNTech	-$2.68	N/A	N/A	N/A	$175.90 million	N/A
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 2024	VTRS Viatris	$0.57	$0.54	-$0.03	-$0.43	$3.60 billion	$3.53 billion
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.47%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.47%	-8.36%	132.50%	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.46%	N/A	N/A	N/A
VTRS Viatris	$0.48	5.72%	+13.30%	N/A	N/A

Latest VTRS, TAK, BNTX, and TEVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/24/2025	VTRS Viatris	quarterly	$0.12	5.2%	3/10/2025	3/10/2025	3/18/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
TAK Takeda Pharmaceutical	0.63	1.31	0.72
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
VTRS Viatris	0.82	1.51	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.55%
VTRS Viatris	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable
VTRS Viatris	37,000	1.19 billion	1.19 billion	Optionable

VTRS, TAK, BNTX, and TEVA Headlines

Recent News About These Companies

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS

April 29 at 1:45 PM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit â€“ VTRS

April 29 at 1:18 PM | globenewswire.com

Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now

April 29 at 1:07 PM | msn.com

Investors in Viatris Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS

April 29 at 12:15 PM | accessnewswire.com

Viatris Inc. Class Action: Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS

April 29 at 10:45 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

April 29 at 10:19 AM | globenewswire.com

VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

April 29 at 10:16 AM | globenewswire.com

Investors who lost money on Viatris Inc. (VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS

April 29 at 9:00 AM | accessnewswire.com

VTRS ALERT: Viatris Inc. (NASDAQ:VTRS) Investors are Reminded of Pending Securities Fraud Class Action – Contact BFA Law by June 3 Deadline

April 29 at 8:38 AM | globenewswire.com

Shareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS

April 29 at 7:15 AM | accessnewswire.com

VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Viatris Inc. to Contact the Firm Today!

April 29 at 7:00 AM | accessnewswire.com

Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS

April 29 at 5:45 AM | prnewswire.com

Viatris on track to close seventh straight session of gains

April 29 at 12:56 AM | msn.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit - VTRS

April 29 at 12:30 AM | accessnewswire.com

Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

April 28 at 7:51 PM | prnewswire.com

VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 28 at 6:45 PM | accessnewswire.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

April 28 at 6:00 PM | accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Viatris Inc. (VTRS) of a Class Action Lawsuit and an Upcoming Deadline

April 28 at 4:45 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

April 28 at 4:15 PM | prnewswire.com

VTRS NOTICE: Viatris Inc. Investors are Notified of the June 3 Class Action Deadline - Contact BFA Law if You Lost Money

April 28 at 3:46 PM | accessnewswire.com

2 Generic Drug Stocks Ready to Surge in 2025

November 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
Buffett’s Next Oil Bet: Why Occidental Is Different
By Jea Yu | April 8, 2025
View Buffett’s Next Oil Bet: Why Occidental Is Different
United States Steel's Crash: An Unmissable Buying Opportunity
By Gabriel Osorio-Mazilli | April 11, 2025
View United States Steel's Crash: An Unmissable Buying Opportunity
IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
By Leo Miller | April 12, 2025
View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead

VTRS, TAK, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$104.04 +0.04 (+0.04%)

As of 03:44 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Takeda Pharmaceutical NYSE:TAK

$15.28 +0.13 (+0.82%)

As of 03:44 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$15.65 +0.63 (+4.21%)

As of 03:44 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Viatris NASDAQ:VTRS

$8.40 +0.15 (+1.76%)

As of 03:44 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time